On May 5, 2010 the U.S.-Israel Science and Technology Foundation hosted the first U.S.-Israel Biotechnology Business Roundtable at the Hyatt Regency Chicago hotel in conjunction with the BIO 2010 International Convention. Ms. Holly Vineyard, Deputy Assistant Secretary for the Middle East, South Asia and Africa and Ms. Naomi Wiegler, Middle East Trade Specialist attended the event on behalf of the U.S. Department of Commerce. Dr. Eli Opper, Chief Scientist for the Government of Israel’s Ministry of Industry, Trade and Labor and Dr. Ora Dar, Biotechnology Advisor to the Chief Scientist both attended the event on behalf of the Government of Israel. The well attended morning event attracted more than forty participants representing biotechnology industry, pharmaceutical industry, technology transfer offices, academic community and state economic development offices. Ann Liebschutz, Executive Director of the U.S.-Israel Science and Technology Foundation
The Office of the Chief Scientist (OCS) located in the Ministry of Industry, Trade and Labor (MOITL) in the Government of Israel, the main source of government R & D funding in Israel, has invested heavily in the life sciences and considers biotechnology to be a preferred industry. Dr. Opper recognized that Israel’s ultimate success in this sector depends in no small part on taking advantage of international alliances – particularly those with the United States. The OCS has established specialized incubators for life sciences and most recently is in the process of establishing a dedicated biotechnology fund in alliance with private sector fund managers to assist with the further development of the biotechnology sector in Israel. The U.S. Department of Commerce is keen to meet the new U.S. national export initiative that challenges the U.S. to double its exports in the next five years. Like, Dr. Ooper, Ms. Vineyard sees expanding two-way trade and cooperation between the U.S. and Israel as a key to achieving biotechnology economic and job growth.
The purpose of the U.S.-Israel Biotechnology Roundable is to provide a platform for interested stakeholders from industry, academia, and government to share their views on ways to expand and improve the U.S.-Israel relationship in the biotechnology sector. The issue of expanding American led multi-national corporations R & D centers to Israel touched on topics such as the positive climate for clinical trials in Israel, intellectual property issues and Israel’s encouraging environment for science. Participants noted that the U.S. remains competitive for biotechnology research and that when R & D centers are spread out too far, management can become difficult and diluted. An idea emerged that we may see more R & D cooperation agreements between multi-nationals and R & D players in diverse sectors in Israel, rather than the location of complete R & D centers in the country. Other topics considered were patent strength issues, financial credit issues and the value of collaboration of scientific exchanges that touches all level of industry and research – from large corporations to small businesses. FDA regulations were also discussed including how to make use of a new FDA permanent representative in Amman, Jordan and a possible internship for Israel based U.S. citizens in the FDA to increase knowledge of FDA processes in Israel.